SR 17018
Novel µ-Opioid Receptor Agonist
SR 17018 is a synthetic µ-opioid receptor (MOP) agonist that has drawn strong interest in pharmacological research due to its unusual receptor phosphorylation profile. Initially proposed as a G-protein-biased agonist, SR 17018 displays unique delayed and persistent receptor signaling unlike any other biased, partial, or full agonist described to date.
Specifications SR 17018
| Product Name | SR 17018 |
| Form | Powder (research grade) |
| Target | µ-Opioid Receptor (MOP) |
| Mechanism | Delayed multisite receptor phosphorylation |
| Reversibility | Naloxone-sensitive |
| Storage | Cool, dry, light-protected environment |
| Availability | 1g, 3g, 5g, 10g |
Key Features of SR 17018
- Displays both partial and full agonist characteristics depending on exposure duration
- Phosphorylation persists for hours after washout — unlike DAMGO or morphine
- Can reverse morphine tolerance and prevent withdrawal in preclinical models
- Activity is naloxone reversible — distinguishing it from buprenorphine
- Valuable tool for understanding MOP signaling pathways
Why Choose SR 17018?
SR 17018 represents a breakthrough model compound for receptor research, providing a rare look into atypical opioid signaling. Its ability to produce strong receptor activity without immediate dephosphorylation has made it a focus of ongoing studies into safer pain therapeutics and addiction management strategies.
Applications SR 17018 (Research Use Only)
- Opioid receptor pharmacology
- Biased signaling hypothesis testing
- Tolerance and withdrawal mechanism studies
- Comparative analysis with DAMGO, morphine, and buprenorphine
⚠️ This product is supplied strictly for laboratory, academic, and forensic research purposes only.
Not for human or veterinary consumption.
Chemical properties and function
- Pain relief:
It has demonstrated analgesic (pain-relieving) effects in animal models, sometimes showing greater potency and efficacy in certain pain types, such as chemotherapy-induced neuropathy.
- Fewer side effects:
Unlike some conventional opioids, SR 17018 has been shown to produce less respiratory depression and, in some models, does not lead to antinociceptive (pain-blocking) tolerance with chronic use.
Note: Supply is limited. Early batches tend to move fast — secure your research quantity today to avoid backorders.-Be sure to check out our other products by visiting the StoutAlkz Shop page.
Reviews
There are no reviews yet.